Nyxoah announces appointment of new CEO Olivier Taelman
Mont-Saint-Guibert, Belgium – 28 November, 2019
Nyxoah S.A., a healthtech company developing neurostimulation-based therapeutic solutions for sleep related disorders, announced today the appointment of Olivier Taelman as new CEO of Nyxoah, following the resignation of Enrique Vega for personal reasons. Nyxoah’s founder and chairman Robert Taub will continue to serve as executive chairman focused on business development and financing.
Olivier Taelman joined Nyxoah in July 2019 as Chief Operating and Commercial Officer with more than 20 years experience in commercial healthcare and general management roles. He spent 15 years within the field of neuromodulation including at Medtronic, Stryker and neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO. He holds an Executive MBA from Wharton and graduated in Biology from the University of Hasselt.
The board and the shareholders of Nyxoah would like to thank Enrique Vega for his contributions to the company including bringing Nyxoah from development stage to CE mark of its Genio® system.